This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

News
6 Jul 2011

Novartis Receives Approval in Japan for Onbrez Inhalation Capsules

Novartis has received approval in Japan for Onbrez Inhalation Capsules for the treatment of chronic obstructive pulmonary disease.

Novartis announced that it has received approval in Japan for Onbrez Inhalation Capsules (indacaterol) 150 mcg once-daily for the treatment of chronic obstructive pulmonary disease (COPD).

 

Onbrez, delivered using the Breezhaler device, belongs to the long-acting beta2-agonist (LABA) class of medicines which help to reduce the symptoms of breathlessness, cough and sputum in COPD patients by increasing bronchodilation, or airflow into the lungs. The Japanese Ministry of Health, Labor and Welfare (MHLW) has approved Onbrez for relief of symptoms due to airway obstruction in COPD (chronic bronchitis and emphysema).

 

The submission was supported by a clinical trial program that included three local clinical studies. The pivotal 12-week Phase III study showed that Onbre

Related News